KURA NASDAQ
Kura Oncology, Inc.
1W: -0.8%
1M: -6.7%
3M: +10.9%
YTD: -4.3%
1Y: +2.1%
3Y: +19.7%
5Y: -44.2%
$9.90
+0.28 (+2.91%)
Pre-Market: $9.97 (+0.07, +0.76%)
Weekly Expected Move ±6.2%
$8
$9
$10
$10
$11
Credit Risk of going bust: lower than 74% of companies Debt: 2.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.8%), Kura Oncology, Inc. would be worth roughly what it owes.
Total debt $24.5M against a stock market value of $880.7M.
Distance to default 8.23 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $7.0M (short-term plus half of long-term), stock volatility 57.8%; Altman Z'' -5.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.8%), Kura Oncology, Inc. would be worth roughly what it owes.
Total debt $24.5M against a stock market value of $880.7M.
Distance to default 8.23 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $7.0M (short-term plus half of long-term), stock volatility 57.8%; Altman Z'' -5.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-11-03
Earliest Filing
2025-07-01
Latest Filing
partner: 5
investor: 1
Counterparties (Filed by KURA)
6 relationshipsCompanies named in KURA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kyowa Kirin, Inc. | — | partner | Entered into a Co-Promotion and Medical Affairs Agreement to co-promote ziftomenib in the United States. | 2025-07-01 | View |
| Kyowa Kirin Co., Ltd. | — | partner | Jointly entered into the Collaboration and License Agreement with Kura Oncology, Inc. and Kyowa Kirin, Inc. | 2025-07-01 | View |
| HCP Life Science REIT, Inc. | — | partner | Lease agreement for principal executive offices and research facilities | 2025-01-14 | View |
| Kyowa Kirin Co., Ltd. | — | partner | Entered into a collaboration and license agreement with Kura Oncology to develop and commercialize ziftomenib globally. | 2024-11-20 | View |
| Kyowa Kirin, Inc. | — | partner | Jointly entered into a collaboration and license agreement with Kura Oncology to develop and commercialize ziftomenib gl | 2024-11-20 | View |
| Bristol-Myers Squibb Company | BMY | investor | Purchased 1,370,171 shares of common stock in a registered direct offering for approximately $25.0 million. | 2022-11-03 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-09 | Other Events | View | |
| 2026-09-08 | Officer/Director Change | View | |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-29 | Officer/Director Change | View | |
| 2026-06-04 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-29 | Amendments to Articles of Incorporation or Bylaws; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-02 | Other Events | View | |
| 2025-11-13 | Other Events | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Other Events | View | |
| 2025-10-16 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-01 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-06-18 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-06 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-06-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR